Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2001Journal of Clinical Oncology

Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMadeleine DuvicNorthwestern UniversityKHKenneth B. HymesBrigham and Women's HospitalPHPeter HealdYale University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Duvic et al. (2001) studied this question.

synapsesocial.com/papers/6a7ee30e366dd125a6c3080ahttps://doi.org/10.1200/jco.2001.19.9.2456
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mycosis Fungoides and Sézary Syndrome2023 · 172 citations
  2. 2Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids1994 · 375 citations
  3. 3DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma1998 · 67 citations
  4. 4ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.1994 · 432 citations
  5. 5Central Hypothyroidism Associated with Retinoid X Receptor–Selective Ligands1999 · 321 citations